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Abstract
Studies have shown that the administration of drugs containing pyrimidine nucleo-
tides, such as uridine triphosphate (UTP) and cytidine monophosphate (CMP), has been 
effective in pain-intensity reductions in patients with painful conditions as diabetic neu-
ropathy, back pain, and cervical and trauma-compressive changes. The combination of 
pyrimidine nucleotides UTP and CMP is part of a peripheral neuro-regenerative process. 
Its pharmacological properties are stimulation of nerve cells proteins synthesis, nerve 
cell membranes synthesis, myelin sheaths synthesis, and neurite sprouting through P2Y 
receptors activation. Herein, chapter will be discussed the combination of UTP and CMP, 
and in some cases, the inclusion of cobalamin (B12 vitamin) that appears to have analgesic 
effects in neuropathic pain secondary to spine structural disorders assigned to a complex 
pharmacodynamic. The mechanisms involved can be both indirect (protein synthesis in 
nerve cells, myelin synthesis, synthesis of MBP, etc.) and direct (P2Y receptor stimulation).
Keywords: nerve injury, nucleotides, peripheral regeneration, purinergic receptors, 
Schwann cells
1. Introduction
Neuropathic pain is defined as a pain caused by primary lesion or damage to the cen-
tral or peripheral nervous system and is an issue that has not been thoroughly studied 
or resolved. Damage may result of compression, cutting, ischemic or metabolic disorders, 
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cellular infiltration, or a combination of these factors [1]. About 50–90% of adults under 
45 years, at some point of their lives, have a spine pain experience, especially in the lower 
back, being the main cause of disability [2]. Studies have shown that the administration of 
drugs containing pyrimidine nucleotides, such as uridine triphosphate (UTP) (Figure 1A) 
and cytidine monophosphate (CMP) (Figure 1B), has been effective reductions in pain 
intensity that have been reported in patients with painful conditions such as diabetic neu-
ropathy, back pain, cervical pain, and trauma-compressive disorders [3–6]. The pyrimidine 
nucleotides UTP and CMP are part of a peripheral neuro-regenerative combination. Its 
pharmacological properties are stimulation of nerve cell synthesis of proteins, synthesis 
of nerve cell membranes, synthesis of myelin sheaths, and neurite sprouting through P2Y 
receptors stimulation [7]. Regarding analgesic capacity itself, pharmacological properties 
of two pyrimidinic nucleotides were experimentally demonstrated by Okada et al. (2010), 
which concluded that the activation of UTP-sensitive P2Y2 and/or P2Y4 receptors produces 
inhibitory effects on spinal pain transmission [8].
To better understand the role of nucleotides on peripheral nervous disorders, first, we need to 
get a brief review on peripheral nervous morphology as well as have the regeneration steps 
highlighted. The aim of this chapter is to clarify all steps and functions of those components 
in regeneration, focused on the relationship among nucleotides and glial cells.
2. Peripheral nervous system
The peripheral nervous system (PNS) consists of (1) peripheral nerves, composed of the set of 
nerve fibers joined by connective tissue and (2) their motor and sensorial endings. In addition, 
nerves can be divided as their innervation—cranial or spinal—and as the types of fibers that 
compose them—sensorial, motor, or mixed [9].
Figure 1. A—molecular structure of uridine triphosphate; B—molecular structure of cytidine monophosphate (CMP).
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The nervous tissue mainly consists of neurons and neuroglia, which helps in neuronal or defense 
activity, aiding in the support and protection of neurons. Each neuron has a cell body (soma) 
from which the axon radiates the nerve impulses to its synaptic terminal, and the dendrites, 
which receive and transmit synaptic information in the body of nerve cells [10]. In addition, 
some axons are surrounded by a myelin sheath, which in the central nervous system (CNS), is 
produced by oligodendrocytes and, in the PNS, by Schwann cells (SCs) [11]. In this way, the 
fibers are capable of conducting the electrical impulse, being called afferents when conducting 
to the CNS, or efferent when conduction starts from the CNS to the target organs [10].
3. Myelination
The myelinated fibers of the PNS are composed of a single axon, which is individually 
wrapped by a single SC [11, 12]. The membrane of SC surrounds the fiber to form a multilami-
nated myelin sheath [9] (Figure 2), isolating the axon and helping in the saltatory conduction 
of electrical signals [11].
Figure 2. Diagram representing the origin of the neuroglial structural components.
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Throughout the maturation process, all immature SCs have the same potential for develop-
ment. When they are associated with axons of greater caliber (above 1 μm), they become 
myelinating SCs, and if they are associated with axons of small diameter, they become mature 
nonmyelinating SCs [13]. In this process, there is a fundamental participation of neurotrophin 
(NT), as nerve growth factor (NGF), which serves as a signaling for tyrosine kinase family 
receptors (TrkA) on axon, promoting an axonal diameter growth. Thus, NGF indirectly par-
ticipates in myelinization of the axon. Besides that, it was observed that, during myelination, 
some cell adhesion molecules are downregulated, such as L1 and polysialylated neural cell 
adhesion molecule (NCAM), being expressed only in nonmyelinated axons [14].
The myelination done by a SC after its differentiation is closely linked both to its ability to 
synthesize a basal lamina and to its deposition. Furthermore, the presence of the axon and its 
intimate relationship with SC is extremely important, since it is in the axon that genes will be 
expressed then will maintain the myelinizing phenotype throughout the whole process [15], 
being the neurofascin gene an example, which plays an important role in the more advanced 
stages of myelination [14].
The axon also plays a key role in the activation through neuregulin of the ErbB2 and ErbB3 
receptors of SCs, which are responsible for signaling the onset of the myelination process 
[16]. Therefore, the activation process occurs both through the inactivation of the signals that 
determine the immature state of SCs, and the activation of pro-myelin signals, which involve 
the transcription factors KROX20, octamer-binding transcription factor 6 (OCT6) and brain 2 
class III POU domain protein (BRN2), NGFI-A-binding proteins 1 and 2 (NAB1/2), phosphati-
dylinositol 3-kinase (PI3K) signaling, and v-ski sarcoma viral oncogene homologue (SKI) [13].
4. Injuries to the peripheral nervous system
PNS axons can regenerate and recover their function after injury, fact that does not occur with 
CNS axons, which do not regenerate spontaneously [17]. However, there are some factors that 
contribute to an inefficient functional recovery, among which are (1) damage to the cell body 
of the neuron due to retrograde degeneration, making regeneration impossible; (2) nonvi-
ability of axonal growth due to nerve injury or subjacent diseases; (3) changes in the central 
circuits in which the injured neurons participate due to the plasticity of the neural connec-
tions; and (4) low specificity of reinnervation by the new axons, when the target organs are 
reinnervated by nerve fibers of different functions [18].
In peripheral neuropathic diseases, changes and symptoms vary depending of injured nerve 
type (motor, sensory, or autonomic) [19]. Hence, injury can lead to different levels of nerve 
fiber damage, including substantial functional loss, resulting in decreased quality of life due 
to permanent changes in motor and sensory functions, as well as secondary problems such 
as neuropathic pain [18]. As a result, several pathophysiological changes, including morpho-
logical and metabolic changes, that occur in the injured site and in the neuron body, in the 
proximal and distal segments [9].
These injuries are common, and their repair is still a problem in microsurgery. One method 
widely accepted by surgeons is to solve the problem with an autologous donor nerve, which 
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is linked to some disadvantages, such as an extra incision to removal of a healthy sensory 
nerve, resulting in a sensory deficit [10]. On the other hand, in cases of chronic axotomy, the 
number of SCs in the distal stump decreases drastically, which makes the regeneration of 
axons difficult [20].
In this way, there are currently no repair techniques that ensure the recovery of normal sen-
sory and motor functions after severe traumatic nervousness. Therefore, new therapeutic 
strategies are needed to potentiate axonal regeneration, promote selective reinnervation of 
the target, and modulate the central reorganization [18].
5. Wallerian degeneration
After nerve injury, the proximal fibers of the trauma are disconnected from the body of the 
neuron, resulting in a loss of muscles innervation, which leads to a total or partial loss of the 
motor, sensorial, and autonomic functions [18, 21]. In this way, a series of cellular altera-
tions is initiated in the distal segment of the injured nerve, triggering the process of Wallerian 
degeneration, in which fragmentation and disintegration of the axons occur [17]. This disin-
tegration is the result of a significant increase of Ca2+ in axoplasm, which is normally main-
tained at low concentrations in a healthy axon. On this way, Ca2+ sensitive protease (calpain) 
is activated, thereby degrading the axon cytoskeleton [22–24].
Wallerian degeneration also leads to removal and recycling of fragments derived from myelin 
rupture. For this, there is a recruitment of (1) macrophages, due to an increase in the permeabil-
ity of blood-nerve-barrier (BNB) [24], contributing to removal of debris, phagocytizing them; 
and (2) SCs, which are dedifferentiated, divide and proliferate, also assisting in this removal 
and regulating factors that regulate Wallerian degeneration and nerve regeneration [12].
Besides that, several molecular changes are observed in the distal stump of the injured nerve, 
such as: (1) elevation of NGF messenger ribonucleic acid (mRNA) concentration, related to 
macrophage migration to the site and increased concentration of interleukin; (2) elevation 
of brain-derived neurotrophic factor (BDNF) mRNA concentration; (3) downregulation of 
NT-3 mRNA after nerve injury; (4) NT-4/5 mRNA decreases in the first hours after trauma 
but increases significantly after 2 weeks; (5) the expression of the transmembrane receptor 
for neurotrophic factors, p75NGFR, increases both in the distal stump and in the repair sites; 
(6) the expression of members of the tyrosine kinase family: trkA receptor is not detected, 
whereas the trkB and trkC levels in the SCs increase; (7) ciliary neutrophic factor (CNTF) 
mRNA decreases dramatically; and (8) rapid upregulation of glial cell line-derived neutro-
phic factor (GDNF) mRNA expression in SCs [25].
6. Peripheral nervous system regeneration
The main function of axonal regeneration is to replace the distal segment of the nerve that 
was lost during degeneration, allowing the reinnervation of peripheral segments and the res-
titution of their functions. Therefore, injured axons of peripheral nervous system are able to 
The Role of Nucleotides in Glial Cells during Peripheral Nerve Trauma and Compressive Disorders
http://dx.doi.org/10.5772/68068
123
regenerate and reinnerve their target organs [21]. In view of this, while the degeneration pro-
cess is happening in distal stump of the axon, the proximal stump regeneration begins, which 
occurs through the retrograde reaction that leads to metabolic changes [21, 26].
Moreover, axonic and myelinic debris were previously removed from the distal part of the 
injured site during the process of Wallerian degeneration by macrophages and CSs [12, 17]. 
The relationship between axons and SCs is intense and essential for regeneration process [27], 
since it is necessary a permissive environment for it. This is provided by the set of (1) extracel-
lular matrix, (2) extracellular matrix proteins (ECMs) or neurostimulatory peptides (LN-1 or 
fragments of LN-1), (3) neutrophic factors, and (4) the SCs themselves [28].
Furthermore, SCs lose their myelinizing phenotype, leaded by a decrease in type III neuregulin 
1. They become dedifferentiated and increase the expression of the growth factor-promoting 
genes [22], which aid the expansion of newly formed growth cones on the regenerating fibers. 
In addition, they regulate extracellular matrix molecules [20]. Thus, to aid the expansion of the 
axon, SCs increase their synthesis of adhesion molecules (CAMs), such as N-CAM, Ng-CAM/
L1, N-cadherin, and L2/HNK-1; secrete ECM proteins, such as laminin (LN), fibronectin (FN), 
heparan sulfate proteoglycans (HSP), and tenascin in the basal membrane; secrete several neu-
rotrophic factors, such as NGF and BDNF, to attract the fibers during their regeneration, being 
captured in the growth cones, incorporated into axon, and transported to the body of the neuron; 
and, together with macrophages, express anti-inflammatory cytokines such as interleukin (IL)-10 
(NGEOW), which inhibit the inflammatory process initiated in Wallerian degeneration [25, 27].
Then, in the beginning of regeneration, it is possible to observe an axonal shoot appearing 
in the distal stump, while the surface of the SCs guides the growth cone, allowing the begin-
ning of myelination [10]. This directional guidance track that provides way for axon growth 
is called Büngner band, which is made up by SCs [24], by the basal membrane where the SCs 
are situated [19], as well as by connective tissue. If the distance to be covered by the new axon 
segment is short, there may be a reinnervation in a healthy muscle. However, if reinnervation 
is delayed, SCs degenerate and no longer promote axon growth. Thus, in addition to atrophy 
in target muscle, the receptivity to synapse formation is lost [22].
In view of the active participation of SCs in the regeneration of peripheral nerves, the use of 
these cells has enabled the development of new strategies for the treatment of peripheral ner-
vous disorders [29], including demyelinating diseases and spinal cord injuries [11].
7. Nucleotids as elements with therapeutical properties
It is known that extracellular nucleotides are fundamental in the regulation of several cellular 
and pathological mechanisms, being important in the control of homeostasis [30–32]. The 
regulation of the increase of other substances in cells, glucose and urea metabolism, and par-
ticipation in inflammatory response processes are among these mechanisms [33, 34].
Nucleotides are monomeric structural units composed by a sugar moiety, attached to one or 
more phosphate groups, and a nitrogenous base, which may be cytosine, adenine, guanine, 
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thymine, or uracil [35]. They are present inside cells playing a key role in several processes, 
such as the regulation of programmed cell death, energy generation, and cellular signaling [36].
The intracellular or physiological function performed by nucleotides is related to the type of 
receptor which this binds [37]. These receptors, known as purinoreceptors, are divided into 
two types: P1, which are adenine selective receptors, and P2, which are subdivided into P2X 
receptors, formed by ionotropic receptors of adenosine triphosphate (ATP), and P2Y coupled 
to G proteins, selective for nucleotides containing adenine and/or uracil [38].
This signaling modulates processes such as endocrine and exocrine secretion, platelet aggre-
gation, cell proliferation, differentiation, bone resorption, inflammation, and healing [36]. In 
addition, P2Y receptors are related to cell survival or death mechanisms in order to promote 
tissue healing and regeneration, an important process in pathological conditions [39].
Several types of nucleotides—such as ATP, UTP and adenosine—act in the nervous system as 
signaling molecules in innumerable processes, such as neurogenesis, migration, neuron dif-
ferentiation, apoptosis, and glial cell proliferation [40]. They may play a specific role, assisting 
in the development of the nervous system and its regeneration, in addition to participating in 
synaptic transmission and neuromodulation [41, 42].
Both the ATP-1 and UTP-2 nucleotides are mostly intracellular. However, both can be secreted 
into the extracellular medium by various mechanisms. One of them is the cellular damage, 
which leads to the release of nucleotides by necrotic or apoptotic cells, thus constituting a danger 
signal. Other mechanisms are exocytosis and transport by vesicles and membrane channels [43].
8. Nucleotids and cobalamin and their application for regeneration
The presence of extracellular nucleotides in the nervous system as signaling and regulatory 
molecules in several processes has been recognized for presenting neuromodulatory function 
involved in several stages of metabolism [44] and because they are potent microglial stimula-
tors in both normal and pathophysiological pathways [45].
P2Y receptor ligands have been shown to be positively regulated in spinal microglial cells fol-
lowing damage in peripheral innervation, contributing for example by aiding the treatment 
of neuropathic pain and stimulating the release of neurotrophic factor from the brain [46]. In 
addition, extracellular nucleotides are capable of interacting with proximal cells, inducing cell 
differentiation and neurite outgrowth in glial cells [39, 47, 48]. Thus, they are molecules that, 
when induced, are effective in the treatment of several peripheral neurological syndromes, 
such as peripheral neuropathy [49, 50].
Another important role that nucleotides play is in the mechanism of macrophages recruit-
ment as well as in the production of interleukins—such as IL-6, IL-9, and IL-13—via activa-
tion of P2Y and mRNA receptors [51–53]. The recruitment of macrophages to the injured site 
is essential for the regeneration of nervous tissue, since it promotes a rapid production of 
myelin in the PNS, as well as formation of myelin associated with glycoproteins and, there-
fore, facilitates nerve regeneration [54].
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The interleukins mentioned above are important mediators of nerve regeneration, which act 
via interleukin receptors [55]. Studies show that IL-6 is not detected in intact nerves; however, 
in injured nerves, it is increased and it is regulated by neurotrophic factors, which are released 
by SCs [56].
Drugs containing nucleotides are prescribed, for example, to patients with neuromuscular 
diseases and diabetic polyneuropathy, since their clinical efficacy has already been studied, 
and in vivo tests have demonstrated their role in accelerating the regeneration of nerves and 
muscles after the sciatic lesion [29]. Mechanisms of tissue restoration have a vital importance 
for regeneration of the PNS, and nucleotides can be used as treatment for these lesions, since 
they play an important role in nerve regeneration [57].
In vitro studies show that UTP has an important costimulatory role in the wound healing 
process, activating, and modulating growth factors, which confirms the role of extracellular 
nucleotides in the process of tissue regeneration [58]. UTP, through the activation of P2Y 
purinergic receptors, induces in the SCs an N-cadherin expression increase which is closely 
related to growth and orientation of axons, besides having an important role in cell adhesion 
and myelination [59].
Derivatives of cytidine have been shown to be beneficial against various pathologies of the 
central nervous system, as well as neurodegenerative diseases. It is able to promote the regen-
eration of nerves in the peripheral nervous tissue and promotes the functional recovery of 
these nerves. Preclinical studies have shown that it promotes nerve regeneration in murine 
models. In addition, cytidine administered alone or in combination has an effect on periph-
eral nerve regeneration in rats, which compounds are believed to have the same function as 
cytidine in the regeneration of peripheral nerves [60, 61].
Evidences have shown that the combination of CMP and UTP has a positive effect on tissue 
regeneration [29, 62], as well as a meta-analysis study showed that P2Y receptor ligands are 
a promising therapeutic strategy for the treatment of neuropathic pain in murine models 
[63]. A clinical study of 26 patients with optic neuropathy–administered cytidine diphosphate 
(CDP)-choline for about 6 months showed that CDP-choline is effective in regenerating optic 
nerves in these patients [64].
Nunes et al. compared the efficacy of uridine and cytidine nucleotides associated or not with 
hydroxycobalamin (Figure 3) in the treatment of signs and symptoms of anemia. They observed 
that the group treated with the three elements achieved better efficacy—corresponding to an 
improvement in laboratory assessments, weight gain, and decreased pain—than the group 
treated only with nucleotides [65]. Another study evaluated the use of the three therapeutic 
elements in the treatment of patients with alcoholic polyneuropathy, and it was observed that 
their use was safe and effective, with decreased pain and improved motor coordination [66].
Further study carried out by Negrão et al. tested the use of uridine nucleotides associated 
with vitamin B12 and folic acid to assess the clinical improvement of patients with peripheral 
neuropathy associated with neuropathic pain. They observed a significant improvement in 
pain intensity, number of affected areas, and pain irradiation, suggesting a possible reduction 
in the use of nonsteroidal anti-inflammatory drugs (NSAIDs) [49].
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Several meta-analysis studies have shown that there is a vitamin B12 deficiency in peripheral 
neuropathies due to type II diabetes, and that the administration of vitamin B12 in these 
patients is efficient as a treatment of neuropathy and neuropathic pain and may even be 
administered as prophylactic supplementation in this population [67–69].
Neurological disorders related to exposure of nitrous oxide anesthesia have been reported and 
are linked to toxicity in the spinal cord, since this substance causes irreversible oxidation of 
the cobalt ion present in the cobalamin structure [70]. In such cases, homocysteine methylation 
for S-adenosyl-methionine (SAM) formation is defective, leading to the formation of unstable 
Figure 3. Molecular structure of cobalamin, Vitamin B12, whose central cobalt atom is attached to a hydroxyl radical.
The Role of Nucleotides in Glial Cells during Peripheral Nerve Trauma and Compressive Disorders
http://dx.doi.org/10.5772/68068
127
myelin basic proteins [71]. Also, clinical study has shown that parenteral administration of vita-
min B12 in a series of cases with different neurological abnormalities, where patients had vita-
min B12 deficiency were effective for the treatment of peripheral neurological damage [72–75].
Vitamin B12 plays an important role in DNA synthesis and neurological functions, and its 
deficiency induces a failure of the methylation of basic myelin proteins and may be the cause 
of myeloneuropathy or peripheral neuropathy [76]. Weir and Scott showed that B12 deficiency 
is very common in the elderly and is important in the brain where SAM synthesis occurs [77]. 
In addition, other pathophysiological conditions such as survivors of acute lymphoblastic 
leukemia during childhood, patients with rare Foster Kennedy syndrome, or patients with 
nitric oxide toxicity, may present neuropathy due to vitamin B12 deficiency, and in these 
cases, the administration of it is used as treatment [76–79].
Futhermore, it is known that vitamin B12 deficiency causes neurological changes that form a 
classic clinical picture of subacute degeneration of the dorsal and lateral vertebral column as a 
consequence of changes in myelin formation [80, 81] and in that cases, the standard treatment 
is the administration of cobalamin [82]. Besides, B vitamins have an analgesic effect in painful 
neuropathic and nociceptive syndromes [83].
9. Molecular perspectives
Endogenous substances when administered exogenously tend to be processed as elements 
belonging to normal physiology, in which homeostatic mechanisms act to bring them back to 
their normal levels [84, 85]. The control of blood levels of nucleosides is exerted by the balance 
between three different metabolic pathways: (1)—hepatic de novo synthesis, (2)—salvage path-
way, (3)—hepatic degradation [86–88]. Both uridine and cytidine pass into the nervous system 
from the choroid plexus and the blood-brain barrier, through nucleoside transport systems [89].
These systems are divided into low-affinity equilibrium transport system (SLC29 family) and 
high-affinity concentration transport system, which is sodium-dependent, substrate-selective 
and unidirectional (SLC28 family) [90]. Both the transport of blood to the cerebral extracel-
lular fluid and the extracellular cerebral fluid to the neural cells are mediated by these trans-
porters [91, 92].
Oral administration of cytidine to humans rapidly elevates uridine serum levels because of 
the conversion of part of it into uridine [93]. Therefore, even if administration of exogenous 
cytidine leads to increased levels of its nucleoside in neural cells, since the uridine is the main 
precursor for CTP used in the synthesis of brain phosphatides [89] (see Figure 4).
The biosynthesis of phosphatidylcholine, the most abundant phospholipid in the brain and 
phosphatidylethanolamine proceeds through activation of the amine moiety (namely choline 
or ethanolamine) by coupling to CDP prior to its addition to the diacylglycerol, leading to the 
production of CDP-choline or CDP ethanolamine and inorganic phosphate [94]. Both cytidine 
and uridine are able to increase neuronal membrane synthesis through increasing levels of 
CTP [95–97].
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The circulating pyrimidines, in addition to being incorporated into nucleic acids, may serve 
as substrates for the salvage route of pyrimidine nucleotide synthesis, as precursors of cyti-
dine triphosphate (CTP) [98] and as precursors for uridine diphosphate (UDP) and uridine 
triphosphate (UTP), which activate the brain's P2Y receptors [99].
Cytidine nucleotides are extremely important for the replacement of phospholipids that serve 
as substrates for cell membrane synthesis in the nervous system, such as phosphatidylinosi-
tol, phosphatidylcholine and phosphatidylethanolamine [89, 100]. In addition, they are also 
involved in the modulation of pain transmission by the activation of P2Y receptors [101].
Uridine nucleotides activate specific P2Y receptor subtypes in humans [102, 103], acting as 
cell-to-cell signaling in the nervous system [104, 105]. They are dependent on the activity 
of the axonal signals in neighboring oligodendrocytes and their structure consists of seven 
transmembrane domains, with the N-terminal domain in the extracellular space and the 
C-terminal domain in the cytoplasm [19, 106]. In addition, activation of P2Y receptors is usu-
ally associated with the stimulation of various mitogen-activated protein kinases (MAPKs), 
mainly the extracellular signal-regulated protein kinase 1/2 [38].
Figure 4. Overview of metabolic pathways (protein synthesis, myelin sheath synthesis, and neuronal cell membrane 
synthesis), to which exogenous nucleotides CMP and UTP integrate. Abbreviations: CDP: cytidine diphosphate; CMP: 
cytidine monophosphate; CTP: cytidine triphosphate; mRNA: messenger ribonucleic acid; NS: nervous system; rRNA: 
ribosomal ribonucleic acid; UDP: uridine diphosphate; UMP: uridine monophosphate; UTP: uridine triphosphate.
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The activation of purinergic receptors in axons and SCs in regeneration processes is vital, 
since their inhibition leads to improper regeneration of the nerve [107]. Physiologically, extra-
cellular UTP is capable of causing secretion in calcium chloride epithelial cells and in glial 
cells of catecholamines. In the SCs, UTP treatment contributes to the increase of the excit-
atory communication between axons and these cells through the secretion of ATP [19] and 
increased N-cadherin expression, an adhesion protein that could reanalyze the early contacts 
between cells and axons to accelerate myelination and axonal regeneration [59].
Subtypes of UTP-activated receptors P2Y2 and P2Y4 in humans are coupled to Gq protein [102] and are mainly involved in long-term effects, such as differentiation, neurite outgrowth, 
and cell survival or death [108, 109]. These receptors are normally activated during patho-
logical conditions and participate in inflammatory processes of the nervous system [102], in 
which they trigger and sustain reactive astrogliosis, the reaction to brain trauma [104, 105], 
characterized by cellular proliferation and neural circuit remodeling [110].
The P2Y2 and P2Y4 receptors activate phospholipase C, increasing the cytosolic Ca2+ concen-
tration from the intracellular reserves and the activation of protein kinase C in response to the 
production of inositol 1,4,5-trisphosphate and diacylglycerol, respectively [111]. Generally, 
P2Y receptors that increase intracellular Ca2+ concentration induce the tricarboxylic acid cycle 
and increase ATP production, which promotes the maintenance of ion homeostasis and anti-
oxidant defense [109].
P2Y2 receptors are expressed by neurons, astrocytes, and microglia and regulate actin polym-
erization and cytoskeletal rearrangements through the Rac/Rho pathways [112], as well as the 
P2Y4 receptors [113]. Its activation confers neuroprotection in several ways: the promotion 
of neurite outgrowth, increased cell motility, nonamyloidogenic processing of the amyloid 
precursor protein, and increased phagocytosis and degradation of the amyloid-beta peptide 
[102, 111]. Moreover, studies have shown that microglia respond rapidly to nerve lesions by 
migrating to the spinal projection territories of the central terminals of injured primary affer-
ents, with subsequent proliferation, activation of p38 MAPK and ERK1/2, and production of 
proinflammatory cytokines and chemokines [114].
UTP also participates in neuromodulation. The modulation exerted by activation of P2Y4 
receptors is linked to the positive influence on excitatory transmission mediated by postsyn-
aptic N-methyl-D-aspartate (NMDA) and α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic 
acid (AMPA) receptors, through increased glutamate release [111], while P2Y2 receptors 
modulation is linked to increased currents through the Ca2+ permeable transient receptors 
potential vanoloyide 1 (TRPV1) in the PNS [115]. This high concentration of intracellular Ca2+ 
can participate in responses through annexins—responsible for signal transduction, traf-
ficking, and vesicle aggregation and membrane organization—that bind negatively charged 
phospholipids in a Ca2+-dependent way [116].
In addition to UTP, other uridine derivatives also activate P2Y receptors, such as UDP, which 
activate the subfamily of P2Y6 and P2Y14 receptors [117, 118]. However, while P2Y6 receptors 
are coupled to Gq/11 protein, P2Y14 receptors are coupled to G protein, and the increase in their expression is also related to the occurrence of peripheral nerve lesions, being regulated 
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by p38 MAPK [114]. The activation of the P2Y6 receptors in microglia cells causes a rapid 
change in their morphology, with phagocytosis of damaged neurons being increased, through 
the reorganization of actin by a pathway mediated by the activation of protein kinase C (PKC) 
and PCL linked to the increase of intracellular Ca2+ [94].
Cobalamin and its analogs act on the nervous system promoting neurite outgrowth and neu-
ronal survival. It plays the role of coenzyme in the methylation of homocysteine by methio-
nine synthase to form methionine, in isomerization of 1-methylmalonyl-CoA in succinyl-CoA 
catalyzed by 1-methylmalonyl-coenzyme A mutase [119, 120], and in the activation of Erk1/2 
and Akt [8].
In addition to the formation of methionine from homocysteine, methionine synthase is 
required for the synthesis of S-Adenosyl-methionine [121, 122]. SAM is a key metabolite in 
amino acid transmethylation responsible for the biological methylations that modify nucleic 
acids, fatty acids, porphyrins, phospholipids, polysaccharides, biogenic amines, and proteins, 
such as myelin basic protein (MBP), one of the proteins responsible for the compaction of the 
cytoplasmic surfaces of the myelin sheath [123, 124].
Vitamin B12, as the effector of methionine synthase, plays a key role in ensuring the integ-
rity and stability of the myelin basic protein, since it depends on the methylation of one of 
its amino acids. A deficiency in this methylation can lead to poor protein formation and 
instability [119]. In addition, methionine also facilitates the formation of formyl tetrahy-
drofolate (formyl THF) and tetrahydrofolate (THF), which are involved in the synthesis of 
purines [125].
Under normal conditions, when the folding and/or trafficking of a polypeptide fails, the pro-
tein is targeted for degradation by the ubiquitin-proteasome system. However, when there is 
a pathologic condition, there is interruption of the balance between the synthesis/folding and 
degradation pathways, and the accumulation and aggregation of proteins are favored, which 
are a characteristic of several neurodegenerative diseases [126].
10. Discussion
Some clinical studies using nucleotides and vitamin B12 for the treatment of diseases of the 
peripheral nervous system have been carried out, proving that CMP, UTP, and hydroxyco-
balamin are effective and can be used safely for this purpose. The studies cited below are 
summarized in Table 1.
Lauretti et al. evaluated the efficacy of oral administration of the cytidine-uridine-hydroxy-
cobalamin complex in the treatment of chronic neuropathic lower back pain. The study 
evaluated 48 adult patients, aged 21–80 years, with a history of pain after 6 months, whose 
previous traditional treatments were ineffective. During the course of treatment, patients 
were given oral fluoxetine (20 mg/day) daily and were divided into two groups: the control 
group, which received a combination of 40-mg lidocaine, 30-mg clonidine, and 10-mg dexa-
methasone, diluted with physiological solution; and study group where a tablet containing 
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Authors Type of study Sample Objectives/methods Results/conclusion
Parisi et al. [64] Clinical study 
of the effects of 
CDP-choline on 
patients with optic 
neuropathy
26 patients were 
treated with 
the disease and 
compared with 14 
normal individuals
Patients were 
treated with oral 
CDP-choline for two 
60-day periods and 
one later to complete 
360 days of study 
initiation. The results 
were evaluated by 
electrophysiological 
exams.
There was a 
significant 
improvement with 
the treatment of 
CDP-choline patients
Nunes et al. [66] Clinical study of the 
use of CMP UTP and 
B12 to treat alcoholic 
polyneuropathy
120 patients between 
18 and 65 years of 
age were evaluated
Patients with 
alcoholic neuropathy 
were treated with 
CMP, UTP and B12 
intramuscularly in 
6 days and orally 
for 30 days and then 
the effects were 
monitored
The combination of 
uridine, cytidine, and 
vitamin B12 was safe 
and effective in the 
treatment of patients 
with alcoholic 
neuropathy
Mibielli et al. [7] The analgesic effects 
of the combination 
UTP, CMP and 
hydroxycobalamin 
were evaluated 
in a self-paired 
evolutionary model
17 men and 24 
women were treated
Analysis of 
previously 
unpublished data 
from investigators 
files on VAS and 
PFQ pain scores 
of the group of 
patients treated with 
the combination 
of UTP, CMP and 
hydroxycobalamin
The combination 
of UTP, CMP and 
hydroxycobalamin 
seems to have 
analgesic properties 
in the medium term
Negrão et al. [49] Clinical evaluation 
of patients 
with peripheral 
neuropathy and 
neuropathic pain
212 patients with 
a mean age of 59 
(±14.4) years of age
Patients received 
daily treatment 
of uridine 
monophosphate + 
folic acid + vitamin 
B12 for 2 months 
in conjunction with 
anti-inflammatories 
and were 
evaluated using 
a pain-detection 
questionnaire
The combination of 
UMP + vitamin B12 + 
folic acid is effective 
against neuropathic 
pain associated 
with peripheral 
neuropathy. The use 
of anti-inflammatory 
decreased by more 
than 70%.
Negrão and Nunes 
[50]
Observational study 
of patients with 
neuropathy
48 patients were 
evaluated
Patients received 
daily treatment 
of uridine 
monophosphate + 
folic acid + vitamin 
B12 for 2 months 
in conjunction with 
analgesics and anti-
inflammatories, and 
were evaluated using 
a pain-detection 
questionnaire
Uridine 
monophosphate + 
folic acid + vitamin 
B12 reduced total 
pain score, intensity 
and characterization 
of pain and 
associated symptoms 
and the use of 
analgesic and anti-
inflammatory drugs 
reduced in 77.4%
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the  cytidine-uridine-hydroxycobalamin complex was added and given orally every 12 hours. 
The results of the study indicated that the co-administration of the complex during treatment 
led to a decrease in the intensity of chronic neuropathic low back pain and a reduction in 
the consumption of rescue analgesics, improving and enhancing the quality of treatment in 
patients with neuropathic low back injuries [6].
Parisi and colleagues used CDP choline to treat optic neuropathy in a study with 26 sick 
patients in the test group and 14 healthy subjects in the control group. The treatment was 
done orally for two 60-day periods and a later period until it was completed 360 days after 
the start of the study. The results were evaluated through electrophysiological examinations, 
leading to a significant improvement in the patients. Thus, it has been found that CDP choline 
can be used to treat patients with optic neuropathy [64].
Goldberg and colleagues evaluated the use of a combination of uridine triphosphate (UTP), 
cytidine monophosphate (CMP), and hydroxocobalamin in a double-blind, randomized 
study in the treatment of neuralgia due to degenerative orthopedic alterations with neural 
compression. The patients were divided into two groups, being Group A: total daily dose 
of 9 mg UTP, 15 mg CMP, 6 mg hydroxycobalamin; and Group B: total daily dose of 6 mg 
hydroxocobalamin. At the end of the 30-day treatment period, there were reductions in 
the pain scale scores in both groups; however, there was a significantly larger reduction 
in the scores of the Group A patients. Based on these findings, the authors concluded that 
the combination of UTP, CMP, and vitamin B12 has a positive effect on pain and func-
tionality improvement in the treatment of degenerative orthopedic alterations with neural 
 compression [127].
Nunes and collaborators administered CMP, UTP, and hydroxycobalamin in patients with 
alcoholic polyneuropathy, a disorder in the peripheral nervous system involving motor, sen-
sorial, and autonomic nerves. This study included 120 patients aged 28–65 years, who were 
treated with doses intramuscularly for 6 days and orally for 30 days. Afterward, the efficacy 
of the treatment was evaluated through sensorial motor tests as well as a visual evaluation of 
pain. With this, it was concluded that the treatment was effective and safe, reducing pain and 
improving the motor activity of the patients [66].
Authors Type of study Sample Objectives/methods Results/conclusion
Solomon [68] A clinical study that 
measured the amount 
of B12 in cancer 
patients associating 
neuropathy and 
neuropathic pain 
with B12 deficiency 
and consequent 
increase in 
malignancy
241 patients were 
evaluated
We evaluated the 
levels of B12 and 
malignancy in 
individuals with 
cancer during a 
period of 4 years in a 
cancer study center
B12 therapy plays 
an important role 
in the prevention 
of neuropathy and 
neuropathic pain 
that are generally 
encountered during 
cancer malignancy 
advances
Table 1. Summarized clinical studies using nucleotides and vitamin B12 for the treatment of diseases of the peripheral 
nervous system.
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Negrão et al. performed an observational clinical study of 212 patients with peripheral neu-
ropathy and neuropathic pain, treated orally for 2 months with capsules of uridine mono-
phosphate (UMP), folic acid, and hydroxycobalamin. These patients had a mean age of 59 
years. The results were evaluated using a questionnaire, where the patient reveals to the doc-
tor the areas of the body that present pain. The result showed that the treatment was effec-
tive, and the statistical analysis showed that there was improvement not only of the overall 
picture but also factors such as intensity of pain and affected areas decreased with treatment. 
In addition, patients greatly reduced the adjunctive use of analgesic or anti-inflammatory 
drugs [49].
In another study, the same group of researchers treated 48 patients with neuropathy or neuro-
pathic pain over a two-month period. Patient evaluations showed a reduction in intensity and 
areas affected by pain, showing the efficacy of the treatment and confirming the results of the 
previous study. As in the previous study, the treatment induced improvement of the patients 
allowing the reduction of analgesic or anti-inflammatory use by up to 70% [50].
Mibielli et al. conducted a clinical study to evaluate the analgesic effects of UTP, CMP, and 
hydroxycobalamin in the treatment of peripheral pain. A total of 17 men and 24 women with 
a mean age of 49 years were treated with oral administration of the compound. The evalu-
ation of the results was performed with a pain questionnaire. The study showed that this 
compound presents analgesic and neuroregenerative properties in the medium term, as well 
as indicated subsequent randomized clinical trials to confirm the results [7].
The increase in the malignancy of some types of cancer is associated with the appearance of 
peripheral neuropathies. A recent study evaluated, over 2 years, levels of vitamin B12 in can-
cer patients at a cancer study center. From the analyses made, it was verified that vitamin B12 
deficiency is associated with the appearance of neuropathies and peripheral pain. Therefore, 
treatment with vitamin B12 may prevent cancer patients from developing neuropathies or 
neuropathic pain [68].
11. Conclusion
New therapeutic strategies are needed to potentiate regeneration in nerve injuries, and the 
use of Schwann cells has enabled the development of new strategies for the treatment of 
peripheral nervous disorders. Numerous studies have been done with the aim of finding 
new targets and new drugs, and the use of uridine and cytidine nucleotides associated with 
hydroxocobalamin has proven to be very effective.
It can be assumed that the nucleotide supplementation of cytidine and uridine associated 
with vitamin B12 in situations of neural structural regeneration can increase its availability in 
SCs, aiding in neuro-regeneration. Therefore, it is a set of drugs that can be used safely in the 
treatment of neuropathies and other diseases associated with degeneration of the peripheral 
nervous system.
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Abbreviations
AMPA α-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid
ATP Adenosine triphosphate
BDNF Brain-derived neurotrophic factor
BNB Blood-nerve-barrier
CAM Cell adhesion molecule
CDP Cytidine diphosphate
CMP Cytidine monophosphate
CNS Central nervous system
CNTF Ciliary neutrophic factor
CTP Cytidine triphosphate
D Day
DNA Deoxyribonucleic acid
ECMs Extracellular matrix
ERK Extracellular signal-regulated kinase
FN Fibronectin
GDNF Glial cell line-derived neutrophic factor
IL Interleukin
LN Laminin
M Month
MAPKs Mitogen-activated protein kinase
MBP Myelin basic protein
NGF Nerve growth factor
NMDA N-methyl-D-aspartate
NSAIDs Nonsteroidal antiinflammatory drugs
NT Neurotrophin
OCT6 Octamerbinding transcription factor 6
PI Phosphatidylinositol
PKC Protein kinase C
PLC Phospholipase C
PNS Peripheral nervous system
RNA Ribonucleic acid
SAM S-adenosyl-methionine
The Role of Nucleotides in Glial Cells during Peripheral Nerve Trauma and Compressive Disorders
http://dx.doi.org/10.5772/68068
135
Author details
Marina Manhães1, Marcelo Cesar1, Rayssa Justo1, Mauro Geller2,, Mendel Suchmacher3 and 
Rafael Cisne1*
*Address all correspondence to: rafael.cisne@gmail.com
1 Fluminense Federal University, Niterói, Brazil
2 Rio de Janeiro Federal University, Rio de Janeiro, Brazil
3 University Center Serra dos Órgãos, Teresópolis, Brazil
References
[1] Woolf CJ. Neuropathic pain. In: Pain. Philadelphia: Lippincott Williams Wilkins, 2004: 
765–95.
[2] Silva GNS, Monteiro PB, Virgínio NA, Souto CGV, Oliveira MVAV. Systematization of 
nursing care for patients with Herniated Disc. Health Science Magazine New Hope. 
2013;11(2):55–71.
[3] Serra JP, Veciana MG, Bordas LB. Therapeutic effects of an association of C.M.P., U.T.P., 
and vitamin B12 in fifty cases of peripheral neuropathies. New England Journal of 
Medicine (Sp Ed). Mayo 1972;VI(64):1–7.
[4] Gallai V, Mazzotta G, Montesi S, Sarchielli P, et al. Effects of uridine in the treatment 
of diabetic neuropathy: an electrophysiological study. Acta Neurologica Scandinavica. 
1992;86:3–7.
[5] Muller D. Treatment of neuropathic pain syndrome. Results of an open study on the 
efficacy of a pyrimidine nucleotide preparation. Fortschritte der Medizin Originalien. 
2002;120:131–3.
SCs Schwann cells
THF Tetrahydrofolate
Trk Tyrosine kinase family
TRPV1 Transient receptor potential vanoloyide 1
UDP Uridine diphosphate
UMP Uridine monophosphate
UTP Uridine triphosphate
V Visit
VAS Visual analogic scale
Peripheral Nerve Regeneration - From Surgery to New Therapeutic Approaches Including Biomaterials and Cell-Based
Therapies Development
136
[6] Lauretti GC, Omals M, Pereira AC, et al. Clinical evaluation of the analgesic effect of the 
cytidine-uridine-hydroxocobalamin complex as a coadjuvant in the treatment of chronic 
neuropathic low back pain. Column. 2004;3(2):73–6.
[7] Mibielli MA, Nunes CP, Scussel AB, Suchmacher Neto M, Oliveira L, Geller M. 
Symptomatic improvement in an acute, non-traumatic spine pain model with a combi-
nation of uridine triphosphate, cytidine monophosphate, and hydroxocobalamin. Pain 
Studies and Treatment. 2014;v. 02, pp. 6–10.
[8] Okada K, Tanaka H, Temporin K, Okamoto M, Kuroda Y, Moritomo H, et al. 
Methylcobalamin increases Erk1/2 and Akt activities through the methylation cycle 
and promotes nerve regeneration in a rat sciatic nerve injury model. Experimental 
Neurology. 2010;222(2):191–203.
[9] Geuna S, Raimondo S, Ronchi G, Di Scipio F, Tos P, Czaja K, Fornaro M. Histology of 
the peripheral nerve and changes occurring during nerve regeneration. International 
Review of Neurobiology. 2009;87:27–46.
[10] Johnson EO, Zoubos AB, Soucacos PN. Regeneration and repair of peripheral nerves. 
Injury. 2005;36(4):S24–9.
[11] Bhatheja K, Field J. Schwann cells: origins and role in axonal maintenance and regenera-
tion. The International Journal of Biochemistry & Cell Biology. 2006;38(12):1995–9.
[12] Campana WM. Schwann cells: activated peripheral glia and their role in neuropathic 
pain. Brain, Behavior, and Immunity. 2007;21(5):522–7.
[13] Jessen KR, Mirsky R. The origin and development of glial cells in peripheral nerves. 
Nature Reviews. Neuroscience. 2005;6(9):671–82.
[14] Sherman DL, Brophy PJ. Mechanisms of axon ensheathment and myelin growth. Nature 
Reviews. Neuroscience. 2005;6(9):683–90.
[15] Garbay B, Heapec AM, Sargueila F, Cassagne C. Myelin synthesis in the peripheral ner-
vous system. Progress in Neurobiology. 2000;61(3):267–304.
[16] Pereira JA, Baumann R, Norrmén C, Somandin C, Miehe M, Jacob C, Lühmann T, 
Manten N, Meijer D, Suter U. Dicer in Schwann cells is required for myelination and 
axonal integrity. Journal of Neuroscience. 2010;30(19):6763–75.
[17] Huebner EA, Strittmatter SM. Axon regeneration in the peripheral and central nervous 
systems. In: Cell Biology of the Axon. 2009. Springer Berlin Heidelberg:305–60.
[18] Navarro X. Neural plasticity after nerve injury and regeneration. International Review 
of Neurobiology. 2009;87:483–505.
[19] Canales TM. Study of the drug CMP Forte and nucleotide UTP in Schwann cells [thesis]. 
Barcelona: International University of Catalonia; 2011.
[20] Jonsson S, Wiberg R, McGrath AM, Novikov LN, Wiberg M, Novikova LN, Kingham PJ. 
Effect of delayed peripheral nerve repair on nerve regeneration, Schwann cell function 
and target muscle recovery. PloS One. 2013;8(2):e56484.
The Role of Nucleotides in Glial Cells during Peripheral Nerve Trauma and Compressive Disorders
http://dx.doi.org/10.5772/68068
137
[21] Allodi I, Udina E, Navarro X. Specificity of peripheral nerve regeneration: interactions at 
the axon level. Progress in Neurobiology. 2012;98(1):16–37.
[22] Scheib J, Höke A. Advances in peripheral nerve regeneration. Nature Reviews. 
Neurology. 2013;9(12):668–76. DOI: 10.1038/nrneurol.2013.227.
[23] Gaudet AD, Popovich PG, Ramer MS. Wallerian degeneration: gaining perspective 
on inflammatory events after peripheral nerve injury. Journal of Neuroinflammation. 
2011;8(1):110.
[24] Ngeow WC. Scar less: a review of methods of scar reduction at sites of  peripheral 
nerve repair. Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endo-
dontology. 2010;109(3):357–66.
[25] Frostick, SP, Qi Yin, Kemp GJ. Schwann cells, neurotrophic factors, and peripheral nerve 
regeneration. Microsurgery. 1998;18(7):397–405.
[26] Zu-Lin C, Yu W-M, Strickland S. Peripheral regeneration. Annual Review of Neuro-
science. 2007;30:209–33.
[27] Webber C, Zochodne D. The nerve regenerative microenvironment: early behavior and 
partnership of axons and Schwann cells. Experimental Neurology. 2010;223(1):51–9.
[28] Bellamkonda RV. Peripheral nerve regeneration: an opinion on channels, scaffolds and 
anisotropy. Biomaterials. 2006;27(19):3515–8.
[29] Martiáñez T, Carrascal M, Lamarca A, Segura M, Durany N, Masgrau R, Abian J, Gella 
A. UTP affects the Schwannoma cell line proteome through P2Y receptors leading to 
cytoskeletal reorganisation. Proteomics. 2012;12(1):145–56.
[30] Baer HP, Drummond GI. Physiological and regulatory functions of adenosine and ade-
nine nucleotides. 1979. Raven Press.
[31] Rudolph FB. The biochemistry and physiology of nucleotides. The Journal of Nutrition. 
1994;124(1 Suppl):124S–7.
[32] Corriden R, Insel PA. New insights regarding the regulation of chemotaxis by nucleo-
tides, adenosine, and their receptors. Purinergic Signalling. 2012;8(3):587–98.
[33] Fausther M, Sévigny J. Nucleosides and extracellular nucleotides regulate hepatic 
functions through a complex system of membrane proteins. Biological Complications. 
2011;334(2):100–17.
[34] Zimmermann H. Extracellular ATP and other nucleotides—ubiquitous triggers of inter-
cellular messenger release. Purinergic Signalling. 2016;12(1):25–57.
[35] Florian J, Leszczyński J. Spontaneous DNA mutations induced by proton transfer in 
the guanine. Cytosine base pairs: an energetic perspective. Journal of the American 
Chemical Society. 1996;118(12):3010–7.
[36] Burnstock G. Pathophysiology and therapeutic potential of purinergic signaling. 
Pharmacological Reviews. 2006;58(1):58–86.
Peripheral Nerve Regeneration - From Surgery to New Therapeutic Approaches Including Biomaterials and Cell-Based
Therapies Development
138
[37] Jacobson KA, Paoletta S, Katritch V, Wu B, Gao Z-G, Zhao Q, et al. Nucleotides act-
ing at P2Y receptors: connecting structure and function. Molecular Pharmacology. 
2015;88(2):220–30.
[38] Burnstock G. Purine and pyrimidine receptors. Cellular and Molecular Life Sciences. 
2007;64(12):1471–83.
[39] Mamedova LK, Gao ZG, Jacobson KA. Regulation of death and survival in astro-
cytes by ADP activating P2Y 1 and P2Y 12 receptors. Biochemical Pharmacology. 
2006;72(8):1031–41.
[40] Ulrich H, Abbracchio MP, Burnstock G. Extrinsic purinergic regulation of neural stem/
progenitor cells: implications for CNS development and repair. Stem Cell Reviews and 
Reports. 2012;8(3):755–67.
[41] Neary JT, Zimmermann H. Trophic functions of nucleotides in the central nervous sys-
tem. Trends in Neurosciences. 2009;32(4):189–98.
[42] Zimmermann H, Braun N. Extracellular metabolism of nucleotides in the nervous sys-
tem. Journal of Autonomic Pharmacology. 1996;16(6):397–400.
[43] Jacobson KA, Boeynaems JM. P2Y nucleotide receptors: promise of therapeutic applica-
tions. Drug Discovery Today. 2010;15(13):570–8.
[44] Ipata PL. Origin, utilization, and recycling of nucleosides in the central nervous system. 
Advances in Physiology Education. 2011;35(4):342–6.
[45] Inoue K. The function of microglia through purinergic receptors: neuropathic pain and 
cytokine release. Pharmacology & Therapeutics. 2006;109(1):210–26.
[46] Tozaki-Saitoh H, Tsuda M, Miyata H, Ueda K, Kohsaka S, Inoue K. P2Y12 receptors in 
spinal microglia are required for neuropathic pain after peripheral nerve injury. Journal 
of Neuroscience. 2008;28(19):4949–56.
[47] Guarnieri S, Pilla R, Morabito C, Sacchetti S, Mancinelli R, Fanò G, Mariggiò MA. 
Extracellular guanosine and GTP promote expression of differentiation markers and 
induce S-phase cell-cycle arrest in human SH-SY5Y neuroblastoma cells. International 
Journal of Developmental Neuroscience. 2009;27(2):135–47.
[48] Menéndez-Méndez A, Díaz-Hernández JI, Miras-Portugal MT. The vesicular nucleotide 
transporter (VNUT) is involved in the extracellular ATP effect on neuronal differentia-
tion. Purinergic Signalling. 2015;11(2):239–49.
[49] Negrão L, Almeida P, Alcino S, Duro H, Libório T, Melo SU, Figueira R, Gonçalves S, 
Neto PL. Effect of the combination of uridine nucleotides, folic acid and vitamin B12 on 
the clinical expression of peripheral neuropathies. Pain management. 2014;4(3):191–6.
[50] Negrão L, Nunes P. Uridine monophosphate, folic acid and vitamin B12 in patients with 
symptomatic peripheral entrapment neuropathies. Pain. 2016;6(1):25–9.
[51] Kobayashi D, Ohkubo S, Nakahata N. Contribution of extracellular signal-regulated 
kinase to UTP-induced interleukin-6 biosynthesis in HaCaT keratinocytes. Journal of 
Pharmacological Sciences. 2006;102(4):368–76.
The Role of Nucleotides in Glial Cells during Peripheral Nerve Trauma and Compressive Disorders
http://dx.doi.org/10.5772/68068
139
[52] Endo Y, Isono K, Kondo M, Tamaoki J, Nagai A. Interleukin-9 and Interleukin-13 aug-
ment UTP-induced Cl ion transport via hCLCA1 expression in a human bronchial epi-
thelial cell line. Clinical & Experimental Allergy. 2007;37(2):219–24.
[53] Zhang Z, Wang Z, Ren H, Yue M, Huang K, Gu H, Liu M, Du B, Qian M. P2Y6 agonist 
uridine 5′-diphosphate promotes host defense against bacterial infection via monocyte 
chemoattractant protein-1–mediated monocytes/macrophages recruitment. The Journal 
of Immunology. 2011;186(9):5376–87.
[54] Stoll G, Jander S, Myers RR. Degenerarion and regeneration os the peripheral nervous 
system: from Augustus Waller’s observations to neuroinflammation. Journal of the 
Pheripheral Nervous System. 2002;7(1):13–27.
[55] Leibinger M, Müller A, Gobrecht P, Diekmann H, Andreadaki A, Fischer D. Interleukin-6 
contributes to CNS axon regeneration upon inflammatory stimulation. Cell Death & 
Disease. 2013;4(4):e609.
[56] Hirota H, Kiyama H, Kishimoto T, Taga T. Accelerated nerve regeneration in mice by 
upregulated expression of interleukin (IL) 6 and IL-6 receptor after trauma. Journal of 
Experimental Medicine. 1996;183(6):2627–34.
[57] Rochkind S, Rousso M, Nissan M, Villarreal M, Barr-Nea L, Rees DG. Systemic effects 
of low-power laser irradiation on the peripheral and central nervous system, cutaneous 
wounds, and burns. Lasers in Surgery and Medicine. 1989;9(2):174–82.
[58] Boucher I, Kehasse A, Marcincin M, Rich C, Rahimi N, Trinkaus-Randall V. Distinct acti-
vation of epidermal growth factor receptor by UTP contributes to epithelial cell wound 
repair. The American Journal of Pathology. 2011;178(3):1092–105.
[59] Martiáñez T, Lamarca A, Casals N, Gella A. N-cadherin expression is regulated by UTP 
in schwannoma cells. Purinergic Signalling. 2013;9(2):259–70.
[60] Aslan E, Kocaeli H, Bekar A, Tolunay S, Ulus IH. CDP-choline and its endogenous 
metabolites, cytidine and choline, promote the nerve regeneration and improve the func-
tional recovery of injured rat sciatic nerves. Neurological Research. 2011;33(7):766–73.
[61] Caner B, Kafa MI, Bekar A, Kurt MA, Karli N, Cansev M, Ulus IH. Intraperitoneal 
administration of CDP-choline or a combination of cytidine plus choline improves nerve 
regeneration and functional recovery in a rat model of sciatic nerve injury. Neurological 
Research. 2012;34(3):238–45.
[62] Pillois X, Chaulet H, Belloc I, Dupuch F, Desgranges C, Gadeau AP. Nucleotide recep-
tors involved in UTP-induced rat arterial smooth muscle cell migration. Circulation 
Research. 2002;90(6):678–81.
[63] Ando RD, Mehesz B, Gyires K, Illes P, Sperlagh B. A comparative analysis of the activity 
of ligands acting at P2X and P2Y receptor subtypes in models of neuropathic, acute and 
inflammatory pain. British Journal of Pharmacology. 2010;159(5):1106–17.
Peripheral Nerve Regeneration - From Surgery to New Therapeutic Approaches Including Biomaterials and Cell-Based
Therapies Development
140
[64] Parisi V, Coppola G, Ziccardi L, Gallinaro G, Falsini B. Cytidine-5′-diphosphocholine 
(Citicoline): a pilot study in patients with non-arteritic ischaemic optic neuropathy. 
European Journal of Neurology. 2008;15(5):465–74.
[65] Nunes CP, Higashi R, Ribeiro MG, de Souza Fonseca A, Leite A, Krymchantowski AV, 
et al. Efficacy and tolerability of a combination of uridine, cytidine, and vitamin B12 
in anemia. A double-blind, comparative study versus nucleotide monotherapy. Revista 
Brasileira de Medicina. 2008;65(1/2):15.
[66] Nunes CP, Scussel Jr AB, Goldberg H, Goldwasser G, Oliveira L, Rzetelna H, et al. 
Alcoholic polyneuropathy: clinical assessment of treatment outcomes following therapy 
with nucleotides and vitamin B12. Research in Neurology: An International Journal. 
2013;2013:g1–16.
[67] Roy RP, Ghosh K, Ghosh M, Acharyya A, Bhattacharya A, Pal M, Chakraborty S, 
Sengupta N. Study of vitamin B12 deficiency and peripheral neuropathy in metformin-
treated early type 2 diabetes mellitus. Indian Journal of Endocrinology and Metabolism. 
2016;20(5):631.
[68] Solomon LR. Functional vitamin B12 deficiency in advanced malignancy: implications 
for the management of neuropathy and neuropathic pain. Supportive Care in Cancer. 
2016a;24(8):3489–94.
[69] Wang D, Zhai JX, Liu DW. Serum folate, vitamin B12 levels and diabetic peripheral neu-
ropathy in type 2 diabetes: a meta-analysis. Molecular and Cellular Endocrinology. 2017. 
163(3), 362–364.
[70] Aubart FC, Sedel F, Vicart S, Lyon-Caen O, & Fontaine, B. Neurological disorders due to 
vitamin B12 deficiency triggered by nitrous oxide. Neurological Review, 2007;163(3):362–4.
[71] Sakly G, Hellara O, Trabelsi A, & Dogui M. Reversible peripheral neuropathy related 
to vitamin B12 deficiency. Neurophysiologie Clinique/Clinical Neurophysiology. 
2005;35(5):149–53.
[72] McCaddon A, Regland B, Hudson P, Davies G. Functional vitamin B12 deficiency and 
Alzheimer disease. Neurology. 2002;58(9):1395–9.
[73] Solomon LR. Vitamin B12-responsive neuropathies: a case series. Nutritional 
Neuroscience. 2016b;19(4):162–8.
[74] Roy S, Sable P, Khaire A, Randhir K, Kale A, Joshi S. Effect of maternal micronutrients 
(folic acid and vitamin B12) and omega 3 fatty acids on indices of brain oxidative stress 
in the offspring. Brain and Development. 2014;36(3):219–27.
[75] Guest J, Bilgin A, Hokin B, Mori TA, Croft KD, Grant R. Novel relationships between 
B12, folate and markers of inflammation, oxidative stress and NAD (H) levels, systemi-
cally and in the CNS of a healthy human cohort. Nutritional Neuroscience. 2015;18(8): 
355–64.
The Role of Nucleotides in Glial Cells during Peripheral Nerve Trauma and Compressive Disorders
http://dx.doi.org/10.5772/68068
141
[76] Petramfar P, Hosseinzadeh F, Mohammadi SS. Pseudo-Foster Kennedy Syndrome as 
a Rare Presentation of Vitamin B12 Deficiency. Iranian Red Crescent Medical Journal. 
2016;18(6):e24610.
[77] Weir DG, Scott JM. Brain function in the elderly: role of vitamin B12 and folate. British 
Medical Bulletin. 1999;55(3):669–82.
[78] Jain P, Gulati S, Toteja GS, Bakhshi S, Seth R, Pandey RM. Serum alpha tocopherol, vita-
min B12, and folate levels in childhood acute lymphoblastic leukemia survivors with 
and without neuropathy. Journal of Child Neurology. 2015;30(6):786–8.
[79] Morris N, Lynch K, Greenberg SA. Severe motor neuropathy or neuronopathy due 
to nitrous oxide toxicity after correction of vitamin B12 deficiency. Muscle & Nerve. 
2015;51(4):614–6.
[80] Flippo TS, Holder WD. Neurologic degeneration associated with nitrous oxide anesthe-
sia in patients with vitamin B12 deficiency. Archives of Surgery. 1993;128(12):1391–5.
[81] Stabler SP. Vitamin B12 deficiency. New England Journal of Medicine. 2013;368(2):149–60.
[82] Butler, CC, Vidal-Alaball, J, Cannings-John, R, McCaddon, A, Hood, K, Papaioannou, 
A, … & Goringe, A. Oral vitamin B12 versus intramuscular vitamin B12 for vitamin 
B12 deficiency: a systematic review of randomized controlled trials. Family Practice. 
2006;23(3):279–85.
[83] Gazoni FM, Malezan WR, Santos FC. B complex vitamins for analgesic therapy. Revista 
Dor. 2016;17(1):52–6.
[84] Dissanayake S. Assessing the bioequivalence of analogues of endogenous substances 
(‘endogenous drugs’): considerations to optimize study design. British Journal of 
Clinical Pharmacology. 2010;69(3):238–44.
[85] Marzo A. Pharmacokinetics of endogenous substances. Bollettino Chimico Farmaceutico. 
1992;131(5):181–4.
[86] Gasser T, Moyer JD, Handschumacher RE. Novel single-pass exchange of circulating 
uridine in rat liver. Science. 1981;213(4509):777–8.
[87] Monks A, Cysyk RL. Uridine regulation by the isolated rat liver: perfusion with an 
artificial oxygen carrier. American Journal of Physiology—Regulatory, Integrative and 
Comparative Physiology. 1982;242(5):R465–70.
[88] Pizzorno G, Cao D, Leffert JJ, Russell RL, Zhang D, Handschumacher RE. Homeostatic 
control of uridine and the role of uridine phosphorylase: a biological and clinical update. 
Biochimica et Biophysica Acta (BBA)-Molecular Basis of Disease. 2002;1587(2):133–44.
[89] Cansev M. Uridine and cytidine in the brain: their transport and utilization. Brain 
Research Reviews. 2006;52(2):389–97.
[90] Pastor-Anglada M, Felipe A, Casado FJ. Transport and mode of action of nucleoside 
derivatives used in chemical and antiviral therapies. Trends in Pharmacological Sciences. 
1998;19(10):424–30.
Peripheral Nerve Regeneration - From Surgery to New Therapeutic Approaches Including Biomaterials and Cell-Based
Therapies Development
142
[91] Lu H, Chen C, Klaassen C. Tissue distribution of concentrative and equilibrative nucle-
oside transporters in male and female rats and mice. Drug Metabolism and Disposition. 
2004;32(12):1455–61.
[92] Redzic ZB, Biringer J, Barnes K, Baldwin SA, Alâ€ Sarraf H, Nicola PA, et al. Polarized 
distribution of nucleoside transporters in rat brain endothelial and choroid plexus epi-
thelial cells. Journal of Neurochemistry. 2005;94(5):1420–6.
[93] Wurtman RJ, Regan M, Ulus I, Yu L. Effect of oral CDP-choline on plasma choline and 
uridine levels in humans. Biochemical Pharmacology. 2000;60(7):989–92.
[94] Lecca D, and Stefania C. Uracil nucleotides: from metabolic intermediates to neuropro-
tection and neuroinflammation. Biochemical Pharmacology. 2008;7510:1869–81.
[95] Wang, L, Pooler, AM, Albrecht, MA, & Wurtman, RJ. Dietary uridine-5′-monophosphate 
supplementation increases potassium-evoked dopamine release and promotes neurite 
outgrowth in aged rats. Journal of Molecular Neuroscience. (2005);27(1):137–45.
[96] Cansev M, and Wurtman RJ. Exogenous cytidine-5′-diphosphocholine increases 
brain cytidine-5′-diphosphocholine levels in gerbils. Journal of Neurochemistry. 
2005;94:105–6.
[97] Savci, V, and Wurtman RJ. Effect of cytidine on membrane phospholipid synthesis in 
rat striatal slices. Journal of Neurochemistry. 1995;641:378–84.
[98] Kennedy EP, Weiss SB. The function of cytidine coenzymes in the biosynthesis of phos-
pholipides. Journal of Biological Chemistry. 1956;222(1):193–214.
[99] Von Kügelgen I. Pharmacological profiles of cloned mammalian P2Y-receptor sub-
types. Pharmacology & Therapeutics. 2006;110(3):415–32.
[100] Bevilacqua J, Downes C, Lowenstein P. Visualization of agonist-stimulated inositol 
phospholipid turnover in individual neurons of the rat cerebral cortex and hippocam-
pus. Neuroscience. 1994;60(4):945–58.
[101] Park SY, Im Kim H, Shin YK, Lee CS, Park M, Song J-H. Modulation of sodium currents 
in rat sensory neurons by nucleotides. Brain Research. 2004;1006(2):168–76.
[102] Beamer E, Gölöncsér F, Horváth G, Bekő K, Otrokocsi L, Koványi B, Sperlágh B. 
Purinergic mechanisms in neuroinflammation: an update from molecules to behavior. 
Neuropharmacology. 2016;104:94–104.
[103] Jacobson, KA, and Müller CE. Medicinal chemistry of adenosine, P2Y and P2X recep-
tors. Neuropharmacology. 2016;104:31–49.
[104] Boccazzi M, Rolando C, Abbracchio MP, Buffo A, Ceruti S. Purines regulate adult 
brain subventricular zone cell functions: contribution of reactive astrocytes. Glia. 
2014;62(3):428–39.
[105] Burnstock G. An introduction to the roles of purinergic signalling in neurodegenera-
tion, neuroprotection and neuroregeneration. Neuropharmacology. 2016;104:4–17.
The Role of Nucleotides in Glial Cells during Peripheral Nerve Trauma and Compressive Disorders
http://dx.doi.org/10.5772/68068
143
[106] Fumagalli M, Lecca D, Abbracchio MP. CNS remyelination as a novel reparative 
approach to neurodegenerative diseases: the roles of purinergic signaling and the P2Y-
like receptor GPR17. Neuropharmacology. 2016;104:82–93.
[107] Vrbova G, Mehra N, Shanmuganathan H, Tyreman N, Schachner M, Gordon T. 
Chemical communication between regenerating motor axons and Schwann cells in the 
growth pathway. European Journal of Neuroscience. 2009;30(3):366–75.
[108] Abbracchio MP, Burnstock G, Verkhratsky A, Zimmermann H. Purinergic signalling in 
the nervous system: an overview. Trends in Neurosciences. 2009;32(1):19–29.
[109] Förster D, Reiser G. Supportive or detrimental roles of P2Y receptors in brain pathol-
ogy? – The two faces of P2Y receptors in stroke and neurodegeneration detected in 
neural cell and in animal model studies. Purinergic Signalling. 2015;11(4):441–54.
[110] Giaume C, Kirchhoff F, Matute C, Reichenbach A, Verkhratsky A. Glia: the fulcrum of 
brain diseases. Cell Death & Differentiation. 2007;14(7):1324–35.
[111] Guzman SJ, Gerevich Z. P2Y receptors in synaptic transmission and plasticity: thera-
peutic potential in cognitive dysfunction. Neural Plasticity. 2016;2016.
[112] Weisman GA, Camden JM, Peterson TS, Ajit D, Woods LT, Erb L. P2 receptors for extra-
cellular nucleotides in the central nervous system: role of P2X7 and P2Y2 receptor inter-
actions in neuroinflammation. Molecular Neurobiology. 2012;46(1):96–113.
[113] Weisman GA, Woods LT, Erb L, & Seye CI. P2Y receptors in the mammalian ner-
vous system: pharmacology, ligands and therapeutic potential. CNS & Neurological 
Disorders-Drug Targets (Formerly Current Drug Targets-CNS & Neurological 
Disorders). 2012b;11(6):722–38.
[114] Kobayashi K, Yamanaka H, Yanamoto F, Okubo M, & Noguchi, K. Multiple P2Y sub-
types in spinal microglia are involved in neuropathic pain after peripheral nerve injury. 
Glia. 2012;60(10):1529–39.
[115] Moriyama T, Iida T, Kobayashi K, Higashi T, Fukuoka T, Tsumura H, et al. Possible 
involvement of P2Y2 metabotropic receptors in ATP-induced transient receptor poten-
tial vanilloid receptor 1-mediated thermal hypersensitivity. Journal of Neuroscience. 
2003;23(14):6058–62.
[116] Lecona E, Turnay J, Nieves O, GuzmÃ¡n-ArÃ¡nguez A, Morgan RO, Fernandez M-P, et 
al. Structural and functional characterization of recombinant mouse annexin A11: influ-
ence of calcium binding. Biochemical Journal. 2003;373(2):437–49.
[117] Abbracchio MP, Boeynaems JM, Barnard EA, Boyer JL, Kennedy C, Miras-Portugal MT, 
… & Burnstock G. Characterization of the UDP-glucose receptor (re-named here the 
P2Y 14 receptor) adds diversity to the P2Y receptor family. Trends in Pharmacological 
Sciences. 2003;24(2):52–5.
[118] Chambers JK, Macdonald LE, Sarau HM, Ames RS, Freeman K, Foley JJ, … & Trill 
J. AG protein-coupled receptor for UDP-glucose. Journal of Biological Chemistry. 
2000;275(15):10767–71.
Peripheral Nerve Regeneration - From Surgery to New Therapeutic Approaches Including Biomaterials and Cell-Based
Therapies Development
144
[119] Sponne IE, Gaire D, Stabler SP, Droesch S, Barbé FM, Allen RH, … & Nicolas JP. 
Inhibition of vitamin B12 metabolism by OH-cobalamin c-lactam in rat oligoden-
drocytes in culture: a model for studying neuropathy due to vitamin B12 deficiency. 
Neuroscience Letters. 2000;288(3):191–4.
[120] Banerjee R, Ragsdale SW. The many faces of Vitamin B12: catalysis by cobalamin-
dependent enzymes 1. Annual Review of Biochemistry. 2003;72(1):209–47.
[121] Clarke R, Smith AD, Jobst KA, Refsum H, Sutton L, Ueland PM. Folate, vitamin B12, 
and serum total homocysteine levels in confirmed Alzheimer disease. Archives of 
Neurology. 1998;55(11):1449–55.
[122] Justo R, Cesar M, Migowski E, Cisne R. Relation between vitamins of the b com-
plex, GABA and glutamate, and their role in neurocognitive disorders-Brief review. 
International Journal of Basic and Applied Sciences. 2016;5(4):229–37.
[123] Ross J, Baldessarini MD. Neuropharmacology of S-adenosyl-L-methionine. The American 
Journal of Medicine. 1987;83(5):95–103.
[124] Surtees R. Biochemical pathogenesis of subacute combined degeneration of the spinal 
cord and brain. Journal of Inherited Metabolic Disease. 1993;16(4):762–70.
[125] Kumar N. Neurologic aspects of cobalamin (B12) deficiency. Handbook of Clinical 
Neurology. 2013;120:915–26.
[126] Fortun J, Verrier JD, Go JC, Madorsky I, Dunn WA, Notterpek L. The formation of 
peripheral myelin protein 22 aggregates is hindered by the enhancement of autophagy 
and expression of cytoplasmic chaperones. Neurobiology of Disease. 2007;25(2):252–65.
[127] Goldberg H, Júnior ABS, Cohen JC, Rzetelna H, Mezitis SGE, Nunes FP, Ozeri D, Daher 
JPL, Nunes CP, Oliveira L, Geller M. Neural compression-induced neuralgias: clinical 
evaluation of the effect of nucleotides associated with vitamin B12. Revista Brasileira de 
Medicina. 2009;66(11):380–5.
The Role of Nucleotides in Glial Cells during Peripheral Nerve Trauma and Compressive Disorders
http://dx.doi.org/10.5772/68068
145

